yttrium radioisotopes has been researched along with Lymphoma, B-Cell, Marginal Zone in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Alhaj Moustafa, M; Hoppe, BS; Jiang, J; Peterson, J; Tun, HW; Wiseman, GA; Witzig, TE | 1 |
| Alhaj Moustafa, M; Borah, BJ; Cerhan, JR; Dholakia, R; Hoppe, BS; Jiang, L; Li, K; Moriarty, JP; Peterson, J; Tun, HW; Witzig, TE | 1 |
| Alderuccio, JP; Lossos, IS; Reis, IM; Rosenblatt, JD | 1 |
| Calabrese, L; Crosta, C; Grana, C; Martinelli, G; Paganelli, G; Pinto, A; Pruneri, G; Radice, D; Rizzo, S; Vanazzi, A | 1 |
| Berkova, Z; Braun, FK; Fanale, MA; Feng, L; Fowler, N; Kwak, LW; Mathur, R; McLaughlin, P; Neelapu, SS; Pro, B; Romaguera, JE; Samaniego, F; Sehgal, L; Selvaraj, V; Shah, JJ | 1 |
| Fabregas, JC; Goodman, D; Hoffman, JE; Hosein, PJ; Koru-Sengul, T; Lossos, IS; Miao, F; Rosenblatt, JD; Serafini, AN; Stefanovic, A | 1 |
| Banay, R; Cabanillas, F; Esmaeli, B; Fayad, L; Gayed, I; Hagemeister, F; Kwak, LW; McLaughlin, P; Neelapu, SS; Pro, B; Romaguera, J; Samaniego, F; Wayne Saville, M | 1 |
| Leahy, MF; Turner, JH | 1 |
| Eidherr, H; Hoffmann, M; Jonak, C; Muellauer, L; Raderer, M; Traub-Weidinger, T; Troch, M | 1 |
| Gisselbrecht, C | 1 |
| Bayer, R; Fung, HC; Gregory, SA; Karmali, R; Kassar, M; O'Brien, T; Shammo, JM; Venugopal, P | 1 |
5 trial(s) available for yttrium radioisotopes and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prospective Studies; Radioimmunotherapy; Recurrence; Rituximab; Salvage Therapy; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2014 |
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Radiation Injuries; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Fatigue; Female; Fever; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Radioimmunotherapy; Remission Induction; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes | 2015 |
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Clinical Trials, Phase II as Topic; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2011 |
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Radiopharmaceuticals; Rituximab; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2011 |
6 other study(ies) available for yttrium radioisotopes and Lymphoma, B-Cell, Marginal Zone
| Article | Year |
|---|---|
Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.
Topics: Antibodies, Monoclonal; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Radioimmunotherapy; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes | 2022 |
Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas.
Topics: Bendamustine Hydrochloride; Cost-Benefit Analysis; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Radioimmunotherapy; Rituximab; Yttrium Radioisotopes | 2023 |
Long-term outcomes of frontline
Topics: Antibodies, Monoclonal; Humans; Lymphoma, B-Cell, Marginal Zone; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes | 2020 |
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Eye Neoplasms; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Radioimmunotherapy; Yttrium Radioisotopes | 2009 |
90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Recurrence, Local; Radioimmunotherapy; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2011 |
A revival: radioimmunotherapy in mucosa associated lymphoid tissue lymphoma.
Topics: Antibodies, Monoclonal; Humans; Lymphoma, B-Cell, Marginal Zone; Radioimmunotherapy; Yttrium Radioisotopes | 2011 |